Pathogenesis and molecular pathophysiology of chronic pancreatitis

Asian Journal of Surgery

Volumn 24, Issue 2, 2001, Pages 85-92

  Kleeff, J ^a   Friess, H ^a   Liao, Q ^a   Esposito, I ^a   Tempia Caliera, A A ^a   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; LECTIN RECEPTOR; PROTEIN P53; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ALCOHOL ABUSE; CHRONIC PANCREATITIS; CLINICAL FEATURE; CONFERENCE PAPER; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; IMMUNE SYSTEM; PANCREAS CANCER; PATHOGENESIS; PATHOLOGICAL ANATOMY;

EID: 0034902665     PISSN: 10159584     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (89)

1. Pathogenesis and epidemiology of chronic pancreatitis
2. A short, eclectic history of exocrine pancreatic insufficiency and chronic pancreatitis
3. Chronic pancreatitis: Still puzzling?
4. Chronic pancreatitis
5. A framework for the aetiogenesis of chronic pancreatitis
6. Evidence that hereditary pancreatitis is a genetically heterogeneous disorder
7. Autoimmune-related pancreatitis is associated with auto-antibodies and a Th1/Th2-type cellular immune response
8. Surgical anatomy of the pancreas and adjacent structures
9. Pancreas
10. Immunopathogenesis of chronic pancreatitis
11. Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma
12. Cytotoxic cells are activated in cellular infiltrates of alcoholic chronic pancreatitis
13. T cell-mediated exocrine pancreatic damage in Major Histocompatibility Complex class II-deficient mice
14. Lymphocytes subsets and cellular immunity in patients with chronic pancreatitis
15. Immune cell infiltration and growth-associated protein-43 expression correlate with pain in chronic pancreatitis
16. Analysis of nerves in chronic pancreatitis
17. Changes in peptidergic innervation in chronic pancreatitis
18. Expression of major histocompatibility antigens in human chronic pancreatitis
19. Phospholipase A2 isoforms are altered in chronic pancreatitis
20. Chemokines - Chemotactic cytokines that mediate inflammation
21. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils
22. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8
23. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes
24. Differential expression of chemokines in normal pancreas and in chronic pancreatitis
25. Expression of interleukin 8 (IL-8) and substance P in human chronic pancreatitis
26. Macrophages infiltrating the tissue in chronic pancreatitis are expressing the chemokine receptor CCR5
27. Signal transduction by receptors with tyrosine kinase activity
28. Growth factor signaling by receptor tyrosine kinases
29. Molecular analysis of signal transduction by growth factors
30. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
31. erbB-2 is a potent oncogene when over-expressed in NIH/3T3 cells
32. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
33. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity
34. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
35. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
36. A subgroup of patients with chronic pancreatitis overexpress the c-erbB-2 protooncogene
37. Overexpression of HER2/neu oncogene in human pancreatic cancer
38. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression
39. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer
40. Transfection with a cripto anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line
41. Cripto, a member of the epidermal growth factor family, is overexpressed in human pancreatic cancer and chronic pancreatitis
42. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
43. Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis
44. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: Evidence for autocrine and paracrine actions
45. Enhanced fibroblast growth factor 5 expression in stromal and exocrine elements of the pancreas in chronic pancreatitis
46. Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice
47. TGF-beta and the extracellular matrix in pancreatitis
48. Expression of transforming growth factor-beta1 in chronic pancreatitis
49. Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis
50. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis
51. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair
52. Nerve growth factor and its high-affinity receptor in chronic pancreatitis
53. Hereditary pancreatitis: New insights into acute and chronic pancreatitis
54. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
55. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis
56. A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis
57. Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation
58. Hereditary pancreatitis-associated mutation asn(21) → ile stabilizes rat trypsinogen in vitro
59. A possible zymogen self-destruct mechanism preventing pancreatic autodigestion
60. Two mutations in rat trypsin confer resistance against autolysis
61. SPINK1/PST1 polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis
62. Pancreatic secretory enzymes
63. Mutations of the cationic trypsinogen gene in patients with chronic pancreatitis
64. Evidence for further mutations of the cationic trypsinogen gene in hereditary pancreatitis
65. Screening for a point mutation of cationic trypsinogen in patients with pancreatic disease
66. Molecular pathogenesis of chronic pancreatitis associated with abnormal CFTR genotypes
67. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis
68. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis
69. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53
70. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia
71. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
72. K-Ras mutations and benign pancreatic disease
73. K-ras mutations at codon 12 are rare events in chronic pancreatitis
74. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases
75. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis
76. Molecular pathology of primary and metastatic ductal pancreatic lesions
77. p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer
78. Pancreatitis and the risk of pancreatic cancer
79. Pancreatitis and pancreatic cancer: A population-based study
80. Genetic alterations in chronic pancreatitis: Evidence for early occurrence of p53 but not K-ras mutations
81. Absence of K-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis
82. A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens
83. Multiple K-ras mutations in hyperplasia and carcinoma in cases of human pancreatic carcinoma
84. Ki-ras oncogene mutations in chronic pancreatitis: Which discriminating ability for malignant potential?
85. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease
86. Duct changes and K-ras mutations in the disease-free pancreas: Analysis of type, age relation and spatial distribution
87. Mutational activation of K-ras in non neoplastic exocrine pancreatic lesions in relation to cigarette smoking status
88. Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice